Clinical Trials
1259
717 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Terminated
5
0.4%
Recruiting
276
21.9%
Active, not recruiting
39
3.1%
Completed
226
17.9%
Unknown
34
2.7%
Not yet recruiting
678
53.9%
No approval data available
- Cipla has secured an exclusive licensing agreement with ImmunoACT to commercialize talicabtagene autoleucel, India's first indigenously developed CAR-T cell therapy, across South Africa, Algeria, and Morocco. - The therapy targets patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma and B-cell Acute Lymphoblastic Leukemia, demonstrating high efficacy and safety in over 500 patients treated in India. - This partnership marks a significant milestone in making advanced cancer immunotherapy accessible in Africa at a fraction of global costs, echoing Cipla's historic role in providing affordable HIV/AIDS drugs to the continent 25 years ago. - The collaboration represents the first international licensing agreement for ImmunoACT, reflecting India's "make in India for the world" initiative in biotechnology innovation.
- The BART trial demonstrated that post-operative radiation therapy reduced locoregional recurrence rates from 26% to 8% in patients with high-risk muscle-invasive bladder cancer. - Two-year locoregional recurrence-free survival improved significantly from 76.4% with observation alone to 91.2% with adjuvant radiation therapy (p=0.004). - The treatment showed minimal toxicity with severe late side effects occurring in only 8.5% of radiation patients versus 10.5% in the observation group. - Subgroup analyses revealed particular benefit for patients with larger tumors (T3-4) and node-positive disease, suggesting potential for personalized treatment approaches.
- India has successfully developed NexCAR19, its first indigenous CAR T-cell therapy for blood cancers, priced at approximately Rs 40 lakh ($50,000) compared to $400,000 in the United States. - Clinical trials involving 64 patients with advanced lymphoma or leukemia showed promising results, with 67% experiencing significant cancer reduction and about half achieving complete remission. - Unlike U.S. approved therapies that use mouse-derived antibody fragments, India's "humanized" CAR T-cells caused fewer severe side effects, with no reported neurologic complications and only 5% experiencing severe cytokine release syndrome.
